0.42
-0.016(-3.71%)
Currency In USD
| Previous Close | 0.43 |
| Open | 0.43 |
| Day High | 0.46 |
| Day Low | 0.41 |
| 52-Week High | 4.9 |
| 52-Week Low | 0.35 |
| Volume | 291,491 |
| Average Volume | 567,495 |
| Market Cap | 13.94M |
| PE | -0.14 |
| EPS | -2.97 |
| Moving Average 50 Days | 0.62 |
| Moving Average 200 Days | 1.19 |
| Change | -0.02 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $4.24 as of May 09, 2025 at a share price of $0.415. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $4.19 as of May 09, 2025 at a share price of $0.415.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 12:00 PM GMT
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the selection of IL1
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
GlobeNewswire Inc.
Apr 25, 2025 12:00 PM GMT
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection w
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of it